Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
D08ZBT
|
|||
Former ID |
DIB015536
|
|||
Drug Name |
SDZ-WAG-994
|
|||
Synonyms |
WAG-994
Click to Show/Hide
|
|||
Drug Type |
Small molecular drug
|
|||
Indication | Hypertension [ICD-11: BA00-BA04; ICD-9: 401] | Discontinued in Phase 1 | [1] | |
Company |
Novartis AG
|
|||
Structure |
Download2D MOL |
|||
Formula |
C17H25N5O4
|
|||
Canonical SMILES |
COC1C(C(OC1N2C=NC3=C(N=CN=C32)NC4CCCCC4)CO)O
|
|||
InChI |
1S/C17H25N5O4/c1-25-14-13(24)11(7-23)26-17(14)22-9-20-12-15(18-8-19-16(12)22)21-10-5-3-2-4-6-10/h8-11,13-14,17,23-24H,2-7H2,1H3,(H,18,19,21)/t11-,13-,14-,17-/m1/s1
|
|||
InChIKey |
JAKAFSGZUXCHLF-LSCFUAHRSA-N
|
|||
CAS Number |
CAS 130714-47-5
|
|||
PubChem Compound ID |
Target and Pathway | Top | |||
---|---|---|---|---|
Target(s) | Adenosine A1 receptor (ADORA1) | Target Info | Agonist | [2] |
KEGG Pathway | cGMP-PKG signaling pathway | |||
cAMP signaling pathway | ||||
Sphingolipid signaling pathway | ||||
Neuroactive ligand-receptor interaction | ||||
Morphine addiction | ||||
NetPath Pathway | TCR Signaling Pathway | |||
RANKL Signaling Pathway | ||||
Panther Pathway | Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | |||
Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway | ||||
Reactome | Adenosine P1 receptors | |||
G alpha (i) signalling events | ||||
WikiPathways | Nucleotide GPCRs | |||
GPCRs, Class A Rhodopsin-like | ||||
GPCR ligand binding | ||||
GPCR downstream signaling |
References | Top | |||
---|---|---|---|---|
REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800003507) | |||
REF 2 | The cardiac effects of a novel A1-adenosine receptor agonist in guinea pig isolated heart. J Pharmacol Exp Ther. 1994 Dec;271(3):1371-82. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.